贝伐单抗治疗卵巢癌：III期研究的批判性综述。
Bevacizumab in ovarian cancer: A critical review of phase III studies.
作者信息
Rossi Luigi, Verrico Monica, Zaccarelli Eleonora, Papa Anselmo, Colonna Maria, Strudel Martina, Vici Patrizia, Bianco Vincenzo, Tomao Federica
机构信息
Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Oncology Unit, "ICOT," Latina, Italy.
Oncology Unit, Dono Svizzero Hospital, Formia, Italy.
出版信息
Oncotarget. 2017 Feb 14;8(7):12389-12405. doi: 10.18632/oncotarget.13310.
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line treatment of advanced OC and for platinum-sensitive and platinum-resistant recurrent OC. These trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, BV effectively improved the quality of life with regard to abdominal symptoms in recurrent OC patients. Bevacizumab is associated with adverse events such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed. This review describes the latest evidence for BV treatment of OC and selection of patients for personalized treatment.
贝伐单抗（BV）是一种靶向血管内皮生长因子的人源化单克隆抗体，是首个用于治疗卵巢癌（OC）的分子靶向药物。随机III期试验评估了BV联合标准化疗用于晚期OC一线治疗以及铂敏感和铂耐药复发性OC的疗效。这些试验报告称，无进展生存期有统计学意义的改善，但总生存期无改善。此外，BV有效改善了复发性OC患者腹部症状方面的生活质量。贝伐单抗与高血压、出血、血栓栓塞、蛋白尿、伤口愈合延迟和胃肠道事件等不良事件相关。然而，这些事件大多可以得到充分管理。本综述描述了BV治疗OC的最新证据以及个性化治疗患者的选择。
Zotero 插件